Previous close | 17.81 |
Open | 17.74 |
Bid | 17.68 x 200 |
Ask | 17.72 x 2700 |
Day's range | 17.56 - 17.89 |
52-week range | 17.51 - 35.38 |
Volume | |
Avg. volume | 12,825,348 |
Market cap | 15.257B |
Beta (5Y monthly) | 0.75 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.00 (5.61%) |
Ex-dividend date | 16 Feb 2024 |
1y target est | N/A |
Walgreens is launching new services and consolidating specialty services to compete in the pharmacy benefits management (PBM) space.
(Bloomberg) -- Walgreens Boots Alliance Inc. is opening a new center dedicated to bringing emerging cell and gene therapies to patients with complex, chronic conditions like cancer, cystic fibrosis and Crohn’s disease.Most Read from BloombergMalaysia in Talks With Tycoons on Casino to Revive $100 Billion Forest CityBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsZuckerberg Asks for Patience as Meta’s AI Push Spooks InvestorsMeta’s Miss Sparks Fears in Tech With More Earn
In this article, we will be taking a look at the 10 best healthcare stocks to buy under $20. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks to Buy Under $20. Global Healthcare Outlook for 2024 As 2024 progresses, the optimism surrounding the healthcare […]